EDSA

Edesa Biotech, Inc. (EDSA) | Rumor.io

Edesa Biotech

EDSA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,484

Bullish sentiment (50-day avg)50%

Price to earnings ratio-2.89

Market capitalization35.2M

Earnings per share-1.72

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-7.2M

Social

What share of all stock conversation is about EDSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Aug 20

Edesa Biotech, Inc. (EDSA) priced a $25M public offering at $5.50/share, including warrants exercisable at $7.50, providing funding for its clinical programs.
The combined public offering price of each common share and accompanying common share warrant is $5.50, with the warrants having an exercise price of $7.50 and expiring on the earlier of 18 months or 30 days following Phase 2 vitiligo topline data release for EB06.
The public offering was seen as a positive sign by some investors, with buyers at $5.50 and the company now having enough cash to last 18 months, potentially creating a bullish trend.

Generated by AI

Sentiment

Of the messages about EDSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.34% +19.4
Bearish	—	—	—	10.66% -19.4

Bullish· May 1

The float for $EDSA is extremely tight, with a "practical float" of only 3.3 million shares, indicating that a large portion of the company's shares are held by institutions and insiders who are unlikely to sell.
The presence of a golden cross on the daily chart suggests a potential long-term bull market for $EDSA, with high trading volumes reinforcing the indicator.
The company's Phase III trials have been highly successful, and the CEO is set to present the results on May 12, which could lead to a significant increase in the stock's value, potentially even a buyout by a big pharma company at a price of $160 per share.

Bearish· May 18

The company's recent announcement failed to provide any new reasons for investors to buy shares, leading to a decline in price.
The company's management has missed opportunities to take the company to the next level, resulting in a loss of investor confidence.
The stock's price is likely to continue falling, potentially reaching as low as $5 per share, due to a combination of factors including a lack of new information and a large number of short sellers.

Generated by AI

Topics

Of the messages about EDSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	30.06%
Technical Analysis	—	—	—	32.54%
Analysts	—	—	—	18.65%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	18.75%

Announcements· Mar 17

The company's stock price surged due to additional positive Phase 3 results for its drug paridiprubart, indicating strong clinical validation and potential regulatory pathway acceleration.
The positive results have triggered an analyst upgrade cycle, which may lead to further revaluation of the stock.
The stock's high-risk profile is attributed to the accelerating analyst upgrade cycle, driven by the positive Phase 3 data for paridiprubart, and the company's potential to re-rate as the catalyst unfolds.

Technical Analysis· Mar 17

$EDSA decisively breached the $5.81 resistance on 8.69M volume, leading to a +35.16% surge to $6.92 with phase 3 catalyst as fundamental confirmation.
The momentum is accelerating, with a technical target aligning at $9.83, and the stock is expected to continue with extreme momentum at +38.76%.
A measured target projects a move toward $10.31, with the stock shattering the $5.88 resistance on huge volume, confirming the breakout and fuelling momentum from recent successful calls.

Generated by AI

Community

Of the messages about EDSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	29.69%
Newcomers	0%	0%	0%	70.31%

Regulars· Mar 6

$EDSA has reached an all-time high in 52 weeks, with a 79% increase in value and a 3x volume-float ratio.
The price is holding higher lows, keeping traders engaged, and if volume expands through resistance, this could lead to a quick run.
Speculative interest in $EDSA is building again ahead of the next potential catalyst window, with the price up 17.34% since the first alert.

Newcomers· Apr 27

The company's lead drug candidate, EB05, has shown positive Phase 3 trial data, reducing mortality in acute respiratory distress syndrome (ARDS) patients.
Edesa Biotech's TLR4 inhibitor, EB05, is a promising treatment for severe inflammation, with a significant market opportunity and no current solutions.
The company has been invited to present at the Respiratory Innovation Summit, a key catalyst for its stock price, and has a share repurchase plan in place, accelerating its growth.

Generated by AI

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded

1mo agoYahoo Finance

Edesa Biotech launches public offering of common shares

1mo agoInvesting.com

Edesa Biotech stock tumbles on public offering launch

1mo agoInvesting.com

Edesa Biotech Announces Proposed Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share warrants to purchase common shares. In addition, Edesa expects to grant the unde

1mo agoYahoo Finance

Also Discussed

Investors talking about EDSA also mention

#	Name	Attention
1	Zivo Bioscience Inc.ZIVO	0%0
2	Eltek Ltd.ELTK	0%new
3	Stabilis Solutions Inc.SLNG	0%0
4	Avalon Holdings Corp. Class A Common StockAWX	0%new
5	NovaBay Pharmaceuticals, Inc.NBY	0%0
6	InflaRx N.V.IFRX	0%new
7	OBLN - Obalon Therapeutics, Inc.	——
8	Innate Pharma S.A. Sponsored ADRIPHA	0%0
9	Legacy Education Inc.LGCY	0%new
10	Bio-Path Holdings Inc.BPTH	0%0

Edesa Biotech, Inc.

Healthcare
Biotechnology

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. Edesa Biotech’s current pipeline centers on host-directed and targeted therapies designed for medical dermatology and respiratory conditions, including investigational programs for acute respiratory distress syndrome, chronic allergic contact dermatitis, vitiligo, systemic sclerosis, and pulmonary fibrosis. The company’s work includes monoclonal antibody and topical treatment candidates intended to modulate immune pathways and address conditions with significant unmet medical needs. Edesa Biotech operates as a research and development organization, advancing its product candidates through clinical studies and related regulatory activities. Headquartered in Markham, Ontario, Canada, the company plays a specialized role in the biotechnology sector by focusing on diseases driven by dysregulated inflammatory and immune responses.

Website

Location

100 Spy Court

Markham, ON, L3R 5H6

Canada

Social

What share of all stock conversation is about EDSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Aug 20

Edesa Biotech, Inc. (EDSA) priced a $25M public offering at $5.50/share, including warrants exercisable at $7.50, providing funding for its clinical programs.
The combined public offering price of each common share and accompanying common share warrant is $5.50, with the warrants having an exercise price of $7.50 and expiring on the earlier of 18 months or 30 days following Phase 2 vitiligo topline data release for EB06.
The public offering was seen as a positive sign by some investors, with buyers at $5.50 and the company now having enough cash to last 18 months, potentially creating a bullish trend.

Generated by AI

Sentiment

Of the messages about EDSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.34% +19.4
Bearish	—	—	—	10.66% -19.4

Bullish· May 1

The float for $EDSA is extremely tight, with a "practical float" of only 3.3 million shares, indicating that a large portion of the company's shares are held by institutions and insiders who are unlikely to sell.
The presence of a golden cross on the daily chart suggests a potential long-term bull market for $EDSA, with high trading volumes reinforcing the indicator.
The company's Phase III trials have been highly successful, and the CEO is set to present the results on May 12, which could lead to a significant increase in the stock's value, potentially even a buyout by a big pharma company at a price of $160 per share.

Bearish· May 18

The company's recent announcement failed to provide any new reasons for investors to buy shares, leading to a decline in price.
The company's management has missed opportunities to take the company to the next level, resulting in a loss of investor confidence.
The stock's price is likely to continue falling, potentially reaching as low as $5 per share, due to a combination of factors including a lack of new information and a large number of short sellers.

Generated by AI

Topics

Of the messages about EDSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	30.06%
Technical Analysis	—	—	—	32.54%
Analysts	—	—	—	18.65%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	18.75%

Announcements· Mar 17

The company's stock price surged due to additional positive Phase 3 results for its drug paridiprubart, indicating strong clinical validation and potential regulatory pathway acceleration.
The positive results have triggered an analyst upgrade cycle, which may lead to further revaluation of the stock.
The stock's high-risk profile is attributed to the accelerating analyst upgrade cycle, driven by the positive Phase 3 data for paridiprubart, and the company's potential to re-rate as the catalyst unfolds.

Technical Analysis· Mar 17

$EDSA decisively breached the $5.81 resistance on 8.69M volume, leading to a +35.16% surge to $6.92 with phase 3 catalyst as fundamental confirmation.
The momentum is accelerating, with a technical target aligning at $9.83, and the stock is expected to continue with extreme momentum at +38.76%.
A measured target projects a move toward $10.31, with the stock shattering the $5.88 resistance on huge volume, confirming the breakout and fuelling momentum from recent successful calls.

Generated by AI

Community

Of the messages about EDSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	29.69%
Newcomers	0%	0%	0%	70.31%

Regulars· Mar 6

$EDSA has reached an all-time high in 52 weeks, with a 79% increase in value and a 3x volume-float ratio.
The price is holding higher lows, keeping traders engaged, and if volume expands through resistance, this could lead to a quick run.
Speculative interest in $EDSA is building again ahead of the next potential catalyst window, with the price up 17.34% since the first alert.

Newcomers· Apr 27

The company's lead drug candidate, EB05, has shown positive Phase 3 trial data, reducing mortality in acute respiratory distress syndrome (ARDS) patients.
Edesa Biotech's TLR4 inhibitor, EB05, is a promising treatment for severe inflammation, with a significant market opportunity and no current solutions.
The company has been invited to present at the Respiratory Innovation Summit, a key catalyst for its stock price, and has a share repurchase plan in place, accelerating its growth.

Generated by AI

Edesa Biotech

Social

Aug 20

Bullish· May 1

Bearish· May 18

Announcements· Mar 17

Technical Analysis· Mar 17

Regulars· Mar 6

Newcomers· Apr 27

Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech prices $25M public offering at $5.50 per share

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Edesa Biotech launches public offering of common shares

Edesa Biotech stock tumbles on public offering launch

Edesa Biotech Announces Proposed Public Offering

Also Discussed

Edesa Biotech, Inc.

Company Information

Location

Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech prices $25M public offering at $5.50 per share

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Edesa Biotech launches public offering of common shares

Edesa Biotech stock tumbles on public offering launch

Edesa Biotech Announces Proposed Public Offering

Also Discussed

Social

Aug 20

Bullish· May 1

Bearish· May 18

Announcements· Mar 17

Technical Analysis· Mar 17

Regulars· Mar 6

Newcomers· Apr 27